Member Info for itsgambling

Cammy. People lie. Results don't. IG

He's full of it. There's no £20k buy showing over the last week. IG

Is always a massive red flag and a sure sign of nervous holders. IG

£20k buy. Hmm. What price did you get? IG

Haha yeah Aviva those fools who don't research. Selling now when all the savvy pi on here are predicting a takeover bid any second. Haha IG

Agreed. This has been the domain of rampers for too long. Some of which I strongly suspect are paid to create a market allowing iis to exit. My expecation is that this will be back in the 20s prior to the huge fund raise needed to rerun p3. Which will take 18 months or more. IG

"The Company will make a further announcement once the New Licence has formally been ratified." This was over 7 weeks ago. Have the company updated yet? I can't see any confirmation? Has this leopard changed its spots or not... IG

Could be that the expected fund raise is finally approaching and a leak is allowing someone to make a quick 30%. IG

Sorry hanibal. Don't see that at all. IMM p3 result was a statistically non significant improvement vs placebo. The investors since results have mostly been rainbow chasers and rampers. They will dissappear as quick as they arrived. The company will be worth much less than it is now when the dust settles. If they decide to run another P3 trial it will take several years again. And cost millions. Takeover speculation will cause any stock to spike. Sadly in IMM I suspect it is just ramping to allow the iis to exit. Best of luck IG

So annoyed I couldn't find anywhere to short IMM at 50p. Writing was on the wall. What an easy trade that would have been. Oh well - am very happy with boring Motif and looking forward to NDA submission completed next week or the week after :-) IG

There is a reason institutional holders are dumping IMM. Same reason we are seeing BOA etc recently investing $10mill+ into Motif. They are interested in fundamentals, and are patient. A 2nd P3 will cost IMM a fortune. And there is very low chance it will ever pass and get FDA approval (IMO). Certainly the time scales are vast. No coincidence that the iis wanted out and magically the share was ramped to death. The ramping crew will leave IMM soon. Lets hope they visit here next. IG

Yep, that stock almost has an mcap as much as MTFB. Madness. It won't last. I was trying to work out how to short it via a CFD earlier but couldn't find a company that offered CFD on AIM. IMM is all based on hype and speculation. Motif has been held back on purpose. Soon enough those who control the market will let it go and the ramping crew will arrive. Patience will be rewarded. I've had a little top up today - now at 340k shares. I'm ready :-) IG

and these ... http://www.eccmidlive.org/#resources/potential-cost-savings-opportunities-with-targeted-iclaprim-icl-compared-to-vancomycin-van-among-hospitalized-patients-with-acute-bacterial-skin-and-skin-structure-infectious-due-to-potential-avoidance-of-van-associated-acute-kidney-injury-abdef37d-61d4-4354-9b0e-d1a6c2b8dfed http://www.eccmidlive.org/#resources/surveillance-of-iclaprim-activity-in-vitro-susceptibility-of-staphylococcus-aureus-resistant-to-clindamycin-tetracycline-and-beta-haemolytic-streptococci-resistant-to-macrolides-tetracyclines-skin-and-skin-structure-pathogens-collected-during-2015-2016-from-europe-5d1f256f-0f86-4201-8144-bc4d428f9fda

http://www.eccmidlive.org/#resources/a-phase-3-randomized-double-blind-multicentre-study-to-evaluate-the-safety-and-efficacy-of-intravenous-iclaprim-versus-vancomycin-in-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-suspected-or-confirmed-to-be-due-to-gram-positive-pathogens-revive-2-86b7a8b3-624d-4bb6-ac77-469a10009328 http://www.eccmidlive.org/#resources/frequency-of-vancomycin-associated-acute-kidney-injury-and-healthcare-utilization-among-veterans-affairs-patients-with-skin-and-skin-structure-infections-2cc04067-891d-431a-b740-03fbdfff6b48

Agreed. This looks very bullish. Clearly the �100k & �200k buyer is confident too :-) Good chance of completely NDA submission next week. IG

Once 37p is traded, we're looking at plain sailing until 51p. Pass 51p and then it gets exciting. Will we get another big buy today ...? IG

Where have you gone, with your giant shoes & rotating bow tie? No '"Observation" today / yesterday about the "Big Buys"????? IG

Over 36p would be a great sign for tomorrow. 5% per day won't take long for interest to build and then it will really move. So many are watching, wondering if this is the long overdue re-rate coming. Those large buys and the size of BOA's position says it is! There is huge interest in this share from the sideline - well they won't be getting my shares, not until well north of �1. IG

FDA will be looking for evidence that the company have followed proper and measurable protocol for alll stages - from manufacture of the drug through to the P3 tests & controls. Given that we have worked closely with them from the start - and that it was previously turned down when submitted by another firm. I am supremely confident that the BOD know what hoops to jump through and will have crossed every t & dotted every i. I'm not worried about AMP holding at all. Both them and the debt holders are now set to benefit when the motif sp rises. And if they have to sell some of their shares, the are clearly big buyers interested (BOA are up to 8%) I wouldn't be so sure that big pharma are not interested. This is a NOVEL AB and will have many applications. Especially important as we humans are becoming resistant to other ABs. It collect / concentrates in the lungs which will be hugely important for many uses. An offer from big pharma at over �1 per share could drop any time - negotiations would be protracted and very secret. Equally we can partner with other small pharma to take this to market. There is a tonne of money to be made from ABSSSI alone - I suggest you watch the latest interview or read one of the presentations. IG

With IMM in mind, it's worth considering the risk v reward here. The risks are extremely low - and reducing again with R2 safety data out. IMO there is almost no risk of us not completing submission in the next few weeks. And very very low risk of the submission not being accepted and subsequently approved. (DYOR about the BOD and P3 results). There is a small risk of dilution via a placement to fund HABP, but yesterdays interview made quite clear that the BOD are looking for other options (MA deals/ licencing) to fund this. If there is a placement in Q3, and a 10-20% drop in sp, this should recover quickly as the benefits of HABP are added in. Also, I expect the sp to be much high prior to a placement being considered. On the other hand, there is the upside. The analyst tagets of > �1 are there for a reason. We are targetting a huge market and each 10% share of our addressable (renally impaired) market is worth $280mill pa! A novel AB is worth $1bn plus on approval. And, of course there is the huge chance of a deal or buy out by/with another pharma, that could appear any day - which is why SandGrove have invested around $10mill! Probably the safest AIM share with a real chance of 4-5 bagging this year. Hence I have over �100k invested here. IG